Skip to main content

Infigratinib Side Effects

Medically reviewed by Last updated on Apr 3, 2024.

Applies to infigratinib: oral capsules.

Side effects include:

Most common (≥20%) adverse reactions include nail toxicity, stomatitis, dry eye, fatigue, alopecia, palmar-plantar erythrodysesthesia syndrome, arthralgia, dysgeusia, constipation, abdominal pain, dry mouth, eyelash changes, diarrhea, dry skin, decreased appetite, blurred vision, and vomiting.

Most common laboratory abnormalities (≥20%) include increased creatinine, increased phosphate, decreased phosphate, increased alkaline phosphatase, decreased hemoglobin, increased lipase, increased calcium, decreased lymphocytes, decreased sodium, increased triglycerides, increased ALT/AST, increased urate, decreased platelets, decreased leukocytes, decreased albumin, increased bilirubin, and decreased potassium.

For Healthcare Professionals

Applies to infigratinib: oral capsule.


Very common (10% or more): Decreased hemoglobin (53%), decrease lymphocytes (43%), decreased platelets (37%), decreased leukocytes (26%), decreased neutrophils (14%), decreased albumin (24%), increased urate (37%)[Ref]


Very common (10% or more): Arthralgia (32%), pain in extremity (17%)

Common (1% to 10%): Fractures[Ref]


Very common (10% or more): Dry eye (44%), eyelash changes (25%), blurred vision (21%), cataracts (12%)[Ref]


Very common (10% or more): Increased phosphate (90%), decreased phosphate (64%), increased lipase (44%), increased calcium (43%), decreased sodium (41%), decreased calcium (10%), increased potassium (17%), decreased potassium (21%), decrease weight (15%)[Ref]


Very common (10% or more): Increased triglycerides (38%), increased alkaline phosphatase (54%), increased alanine aminotransferase (51%), increased cholesterol (18%), increased bilirubin (24%), increased aspartate aminotransferase (38%), increased lipase (44%)[Ref]


Very common (10% or more): Epistaxis (18%)[Ref]

Nervous system

Very common (10% or more): Fatigue (44%), dysgeusia (32%)[Ref]


Very common (10% or more): Increased creatinine (93%)[Ref]


Very common (10% or more): Edema/peripheral edema (17%)[Ref]


Very common (10% or more): Nail toxicity (57%), alopecia (38%), dry skin (23%), palmar-plantar erythrodysesthesia syndrome (33%)[Ref]


Very common (10% or more): Stomatitis (56), constipation (30%), abdominal pain (26%), dry mouth (25%), diarrhea (24%), vomiting (21%), nausea (19%), dyspepsia (17%)[Ref]


Serious adverse reactions in 2% or more patients included infections, anemia, pyrexia, abdominal pain, hypercalcemia, and sepsis. Fatal adverse reactions occurred in 1 (0.9%) patient. Adverse reactions requiring permanent discontinuation in 1% or more patients were blood creatinine increased, fatigue, subretinal fluid, and calcinosis.[Ref]


1. (2021) "Product Information. Truseltiq (infigratinib)." QED Therapeutics Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.